|
|
Article: Actonel reduces vertebral, nonvertebral fracture risk.
- Article from:
- Women's Health Weekly
- Article date:
- November 4, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 NOV 4 - (NewsRx.com & NewsRx.net) -- A new analysis shows that Actonel (risedronate sodium tablets) treatment up to 3 years significantly reduces the risk of vertebral and nonvertebral fragility fracture by 75% in postmenopausal women with osteopenia.
These data were presented during an oral presentation at The North American Menopause Society (NAMS) annual meeting.
"Postmenopausal women with a bone mineral density (BMD) score above the osteoporosis threshold could still be at risk of fracture since other factors besides low BMD contribute to fracture risk," said James A. Simon, clinical professor of obstetrics and gynecology at George Washington ...